Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

AI-Powered TIL Analysis by Lunit Unveils Prognostic Insights for Colon Cancer – published in npj Precision Oncology

 Lunit  a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, published a new study in npj Precision Oncology (Nature Partner Journal), using Lunit SCOPE IO to predict prognosis in stage II–III colon cancer via AI-powered spatial analysis of tumor-infiltrating lymphocytes (TIL). This study showed that Lunit SCOPE IO and the power of AI for spatial TIL analysis can provide clinicians with a practical and efficient tool to enhance prognosis prediction.

AIThority Predictions Series 2024 banner

AIThority News:Core BTS Announces New AI Consulting Services to Help Clients Accelerate use of GenAI Technologies

Traditionally recognized as a biomarker that can be related to cancer prognosis, TIL densities in the tumor microenvironment (TME) offer valuable insights into the patient’s immune response to the tumor. However, the manual evaluation of TIL densities has been laborious and time-consuming, even requiring additional steps in tissue preparation, such as special lymphocyte staining. Moreover, manual evaluation is prone to variability between observers.

The study utilized Lunit SCOPE IO, Lunit’s AI-powered hematoxylin and eosin (H&E) whole-slide image (WSI) analyzer, to evaluate intratumoral TIL (iTIL) and tumor-related stromal TIL (sTIL) densities from WSIs of 289 patients with stage II–III colon cancer treated with surgery and adjuvant therapy. Patients with confirmed recurrences showed significantly lower sTIL densities compared to those with no recurrence (mean sTIL density 630.2/mm2 in cases with confirmed recurrence vs. 1021.3/mm2 in no recurrence).

Related Posts
1 of 40,195

The study also identified distinct risk groups: patients with the lowest iTIL and sTIL were grouped as high-risk, patients with higher sTIL than the median as low-risk, and intermediate-risk group. These groups were predictive of recurrence-free survival time and were independently associated with clinical outcomes after adjusting for other clinical factors. This result suggests that AI-powered TIL analysis can provide practical and reliable prognostic information for stage II–III colon cancer.

Generative AI News:Core BTS Announces New AI Consulting Services to Help Clients Accelerate use of GenAI Technologies

“Despite progress in colon cancer treatments, we still see a relapse in about 20–30% of stage II–III patients. This underscores the need for more precise prognostic biomarkers,” said Brandon Suh, CEO of Lunit. “With the integration of AI, Lunit’s innovative approach not only simplifies the evaluation process but also holds the potential to guide treatment decisions and improve patient outcomes with a tailored approach.”

Recommended AI News: New Slack Innovations and Salesforce Customer 360 Integrations Unlock Team Productivity, Adding Value to the Digital HQ

[To share your insights with us, please write to sghosh@martechseries.com]

Comments are closed.